Patients (n = 76) with carcinoids harboring a favorable marker profile (Ki-67 < 5%, mitotic count < 2 per 2 mm2, and OTP or CD44 positivity) exclusively did not develop distant metastases during follow-up. This evidence concerns the gene CD44 and carcinoid tumor.